logo

For the Inventor, By the Inventor

IE

Janssen Alzheimer Immunotherapy

Calculating rank
USPTO Granted Patents = 23

% Expired Patents = 60.9



Forward Citations = 512

Loading Chart...
Loading Chart...

29 inventors (with patents filed for the assignee):

goldMedal Dale Bernard Schenk (9 out of 72 patents)

silverMedal Guriq Basi (5 out of 10 patents)

bronzeMedal Jose William Saldanha (3 out of 49 patents)

4.  Ranganathan Godavarti (3 out of 6 patents)

5.  Timothy Iskra (3 out of 4 patents)

6.  Theodore A Yednock (2 out of 26 patents)

7.  Ivan Lieberburg (2 out of 10 patents)

8.  James Callaway (2 out of 13 patents)

9.  Michael Grundman (2 out of 5 patents)

10.  Jack Steven Jacobsen (2 out of 11 patents)

11.  Angela Kantor (2 out of 5 patents)

12.  Nicki Vasquez (2 out of 3 patents)

13.  Donna L Luisi (2 out of 3 patents)

14.  Nicholas W Warne (2 out of 17 patents)

15.  Rasappa Gounder Arumugham (1 out of 12 patents)


23 patents:

1. 8916165 - Humanized Aβ antibodies for use in improving cognition (2014-12-23),
2. 8784810 - Treatment of amyloidogenic diseases (2014-07-22),
3. 8642044 - Prevention and treatment of amyloidogenic disease (2014-02-04),
4. 8613920 - Treatment of amyloidogenic diseases (2013-12-24),
5. 8535673 - Prevention and treatment of amyloidogenic disease (2013-09-17),
6. 8440799 - Methods of purifying anti A β antibodies (2013-05-14),
7. 8357781 - Neuroactive fragments of APP (2013-01-22),
8. 8318164 - Anti A beta antibody formulation (2012-11-27),
9. 8227403 - A-β immunogenic peptide carrier conjugates and methods of producing same (2012-07-24),
10. 8128928 - Humanized antibodies that recognize beta amyloid peptide (2012-03-06),
11. 8034348 - Prevention and treatment of amyloidogenic disease (2011-10-11),
12. 8034339 - Prevention and treatment of amyloidogenic disease (2011-10-11),
13. 8003097 - Treatment of cerebral amyloid angiopathy (2011-08-23),
14. 7964192 - Prevention and treatment of amyloidgenic disease (2011-06-21),
15. 7893214 - Humanized antibodies that recognize beta amyloid peptide (2011-02-22),
Company Overview
Janssen Alzheimer Immunotherapy, based in Ireland, is dedicated to advancing the understanding and treatment of Alzheimer’s disease through innovative immunotherapy approaches. The organization focuses on developing therapies that target the underlying mechanisms of neurodegeneration, aiming to improve patient outcomes and quality of life. With a commitment to research and collaboration, Janssen seeks to contribute significantly to the field of neurodegenerative diseases, leveraging cutting-edge science to address unmet medical needs.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

23 Patents

#3 in

#104 in Ireland

#27,736 in the World

IE
IE

Janssen Alzheimer Immunotherapy

Forward Citations = 512

29 inventors:

goldMedal Dale Bernard Schenk (9 out of 72 patents)

silverMedal Guriq Basi (5 out of 10 patents)

bronzeMedal Jose William Saldanha (3 out of 49 patents)

4.  Ranganathan Godavarti (3 out of 6 patents)

5.  Timothy Iskra (3 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Janssen Alzheimer Immunotherapy. Retrieved from https://idiyas.com/company/janssen-alzheimer-immunotherapy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…